Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo-oxygenase inhibitors

European Journal of Pain

Volumn 13, Issue 5, 2009, Pages 448-457

  Huntjens, Dymphy R H ^a   Spalding, David J M ^b   Danhof, Meindert ^a   Della Pasqua, Oscar E ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Allodynia; Biomarker; COX inhibitors; Drug screening; Freund's complete adjuvant; Hyperalgesia; In vivo pharmacology; Inflammatory pain; NSAIDs

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FREUND ADJUVANT; KETOROLAC; NAPROXEN; PLACEBO; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE B2;

ALLODYNIA; ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; HYPERALGESIA; MALE; NONHUMAN; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; TREATMENT RESPONSE; WEIGHT BEARING;

ANIMALS; BEHAVIOR, ANIMAL; BIOLOGICAL MARKERS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; ENDPOINT DETERMINATION; FREUND'S ADJUVANT; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MEMBRANE PROTEINS; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; THROMBOXANE B2; TIME FACTORS;

EID: 63649157096     PISSN: 10903801     EISSN: 15322149     Source Type: Journal    
DOI: 10.1016/j.ejpain.2008.06.011     Document Type: Article

References (29)

1. Anderson G.D., Hauser S.D., McGarity K.L., Bremer M.E., Isakson P.C., and Gregory S.A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 97 (1996) 2672-2679
2. Baillie T.A., Halpin R.A., Matuszewski B.K., Geer L.A., Chavez-Eng C.M., Dean D., et al. Mechanistic studies on the reversible metabolism of rofecoxib to 5-hydroxyrofecoxib in the rat: evidence for transient ring opening of a substituted 2-furanone derivative using stable isotope-labeling techniques. Drug Metab Dispos 29 (2001) 1614-1628
3. Bove S.E., Calcaterra S.L., Brooker R.M., Huber C.M., Guzman R.E., Juneau P.L., et al. Weight bearing as a measure of disease progression and efficacy of anti-inflammatory compounds in a model of monosodium iodoacetate-induced osteoarthritis. Osteoarthritis Cartilage 11 (2003) 821-830
4. ′-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclo-oxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290 (1999) 551-560
5. Esser R., Berry C., Du Z., Dawson J., Fox A., Fujimoto R.A., et al. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. Br J Pharmacol 144 (2005) 538-550
6. Field M.J., Bramwell S., Hughes J., and Singh L. Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones?. Pain 83 (1999) 303-311
7. Fox A., Medhurst S., Courade J.P., Glatt M., Dawson J., Urban L., et al. Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain 107 (2004) 33-40
8. Giuliano F., and Warner T.D. Origins of prostaglandin E2: involvements of cyclooxygenase (COX)-1 and COX-2 in human and rat systems. J Pharmacol Exp Ther 303 (2002) 1001-1006
9. Hay C.H., Trevethick M.A., Wheeldon A., Bowers J.S., and de Belleroche J.S. The potential role of spinal cord cyclooxygenase-2 in the development of Freund's complete adjuvant-induced changes in hyperalgesia and allodynia. Neuroscience 78 (1997) 843-850
10. Huntjens D.R., Danhof M., and Della Pasqua O.E. Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology (Oxford) 44 (2005) 846-859
11. Huntjens D.R., Strougo A., Chain A., Metcalf A., Summerfield S., Spalding D.J., et al. Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats. Br J Pharmacol 153 (2008) 1072-1084
12. Jett M.F., Ramesha C.S., Brown C.D., Chiu S., Emmett C., Voronin T., et al. Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. J Pharmacol Exp Ther 288 (1999) 1288-1297
13. Kato S., Ogawa Y., Kanatsu K., Okayama M., Watanabe T., Arakawa T., et al. Ulcerogenic influence of selective cyclooxygenase-2 inhibitors in the rat stomach with adjuvant-induced arthritis. J Pharmacol Exp Ther 303 (2002) 503-509
14. Lu Y., and Westlund K.N. Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. J Pharmacol Exp Ther 290 (1999) 214-219
15. Matson D.J., Broom D.C., Carson S.R., Baldassari J., Kehne J., and Cortright D.N. Inflammation-induced reduction of spontaneous activity by adjuvant: a novel model to study the effect of analgesics in rats. J Pharmacol Exp Ther 320 (2007) 194-201
16. Nagakura Y., Okada M., Kohara A., Kiso T., Toya T., Iwai A., et al. Allodynia and hyperalgesia in adjuvant-induced arthritic rats: time-course of progression and efficacy of analgesics. J Pharmacol Exp Ther 306 (2003) 490-497
17. Randall L.O., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch Int Pharmacodyn Ther 111 (1957) 409-419
18. Riendeau D., Percival M.D., Brideau C., Charleson S., Dube D., Ethier D., et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 296 (2001) 558-566
19. Scholz J., and Woolf C.J. Can we conquer pain?. Nat Neurosci 5 Suppl (2002) 1062-1067
20. Tedesco L.S., Fuseler J., Grisham M., Wolf R., and Roerig S.C. Therapeutic administration of nitric oxide synthase inhibitors reverses hyperalgesia but not inflammation in a rat model of polyarthritis. Pain 95 (2002) 215-223
21. Vane J.R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 231 (1971) 232-235
22. Vane J. Towards a better aspirin. Nature 367 (1994) 215-216
23. Vane JR, Botting RM. Formation and actions of prostaglandins and inhibition of their synthesis. In: Vane JR, Botting RM, editors. Therapeutic roles of selective COX-2 inhibitors. London: William Harvey Press; 2001, p. 1-47.
24. Wallace J.L., Chapman K., and McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 126 (1999) 1200-1204
25. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 96 (1999) 7563-7568
26. Warner T.D., Vojnovic I., Bishop-Bailey D., and Mitchell J.A. Influence of plasma protein on the potencies of inhibitors of cyclooxygenase-1 and -2. FASEB J 20 (2006) 542-544
27. Wilson A.W., Medhurst S.J., Dixon C.I., Bontoft N.C., Winyard L.A., Brackenborough K.T., et al. An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models. Eur J Pain 10 (2006) 537-549
28. Woolf C.J., Allchorne A., Safieh-Garabedian B., and Poole S. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br J Pharmacol 121 (1997) 417-424
29. Zhang Y., Shaffer A., Portanova J., Seibert K., and Isakson P.C. Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production. J Pharmacol Exp Ther 283 (1997) 1069-1075